PART I Business Overview We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We bel...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001730463-26-000038 | EDGAR | 145K words |
| 2025-03-20 | 2024-12-31 | 0001730463-25-000019 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001730463-24-000048 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001730463-25-000088 | EDGAR | 33K words |
| 2025-08-12 | 2025-06-30 | 0001730463-25-000067 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001730463-25-000039 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001730463-24-000136 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001730463-24-000093 | EDGAR | — |
| 2024-05-17 | 2024-03-31 | 0001730463-24-000064 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001730463-23-000110 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001730463-26-000032 | EDGAR | 1K words |
| 2026-01-26 | 0001730463-26-000019 | EDGAR | — |
| 2026-01-12 | 0001730463-26-000012 | EDGAR | — |
| 2025-12-02 | 0001730463-25-000095 | EDGAR | — |
| 2025-11-12 | 0001730463-25-000081 | EDGAR | — |
| 2025-08-12 | 0001730463-25-000064 | EDGAR | — |
| 2025-06-27 | 0001730463-25-000046 | EDGAR | — |
| 2025-06-02 | 0001730463-25-000043 | EDGAR | — |
| 2025-05-30 | 0001193125-25-132111 | EDGAR | — |
| 2025-05-08 | 0001730463-25-000032 | EDGAR | — |
116 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001730463 |
| Ticker | AUTL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | X0 |
| Website | https://www.autolus.com |
| Listed | 2018-06-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report